|
業務類別
|
Biotechnology |
|
業務概覽
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable. |
| 公司地址
| 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105 |
| 電話號碼
| +1 626 304-3400 |
| 傳真號碼
| +1 626 304-3401 |
| 公司網頁
| https://www.arrowheadpharma.com |
| 員工數量
| 711 |
| Dr. Christopher Anzalone,PhD |
Chairman of the Board, Chief Executive Officer and President |
美元 981.05K |
27/01/2026 |
| Mr. James Hamilton |
Chief of Discovery and Translational Medicine |
美元 617.51K |
29/01/2025 |
| Mr. Patrick C. O'Brien |
Chief Operating Officer, General Counsel and Corporate Secretary |
美元 653.94K |
29/01/2025 |
| Mr. Daniel Apel |
Chief Financial Officer and Principal Accounting Officer |
美元 232.21K |
25/11/2025 |
|
|
| Dr. Michael S. Perry, PhD |
Independent Director |
27/01/2026 |
| Dr. Christopher Anzalone,PhD |
Chairman of the Board, Chief Executive Officer and President |
27/01/2026 |
| Dr. Mauro Ferrari, PhD |
Independent Director |
27/01/2026 |
| Dr. Adeoye Olukotun, M.D.,M.P.H. |
Independent Director |
27/01/2026 |
| Dr. Hongbo Lu, PhD |
Independent Director |
27/01/2026 |
| Mr. William D. Waddill |
Lead Independent Director |
27/01/2026 |
| Ms. Victoria Vakiener |
Independent Director |
27/01/2026 |
| Mr. Douglas S. Ingram,Esq. |
Independent Director |
27/01/2026 |
|
|
|
|
